Businesswire·2025-12-19 16:45Core Viewpoint - STAAR Surgical Company has announced the adjournment of its Special Meeting of Stockholders regarding the Alcon merger agreement, now rescheduled for January 6, 2026, due to Alcon exercising its right under the merger agreement [1]. Company Overview - STAAR Surgical (NASDAQ: STAA) is a leader in implantable phakic intraocular lenses, providing vision correction solutions that can reduce or eliminate the need for glasses or contact lenses [2]. - The company has been focused solely on ophthalmic surgery since 1982 and has sold over 3 million ICLs in more than 75 countries [2]. - STAAR's EVO ICL™ product line offers a minimally invasive procedure for vision correction without removing corneal tissue or the eye's natural crystalline lens [2]. Merger Information - The Special Meeting of Stockholders was originally scheduled for December 19, 2025, and the record date for eligible stockholders remains October 24, 2025 [1]. - Relevant materials regarding the proposed transaction have been filed with the U.S. Securities and Exchange Commission (SEC), including a definitive proxy statement on September 16, 2025 [3].